HEALTH

Omron Healthcare, Dr. Oz team up to underscore home blood-pressure monitoring

BY Michael Johnsen

BANNOCKBURN, Ill. Omron Healthcare has joined forces with "The Dr. Oz Show" in an integrated media partnership to help spread the word about the importance of home blood pressure monitoring, Omron announced Thursday.

 

“High blood pressure is a growing concern in the United States among adults, and is often referred to as the ‘silent killer,’” stated Ranndy Kellogg, Omron Healthcare VP marketing and product development. “We’re thrilled to align with ‘America’s Doctor’ in the Sept. 7 season premier to help spread the word about the importance of home blood pressure monitoring, further helping to decrease the risk of heart disease and increase life expectancy.”

 

 

The Omron Healthcare integration includes a sponsored segment on "The Dr. Oz Show’s" premiere episode, in addition to a consumer incentive that will be revealed by Dr. Oz during the show. The first 50,000 visitors to DoctorOz.com will be able to download a $10 coupon good on any Omron Healthcare home blood pressure monitor at participating retailers.

 

 

The second season of "The Dr. Oz Show" will stress to viewers to “Know Your Five,” and blood pressure is one of those lifesaving numbers Americans need to know. As many as 1-in-3 people suffer from high blood pressure, according to the American Heart Association. And, research showed home blood pressure monitoring can be vital to reducing a patient’s risk of stroke, heart attack, heart failure or kidney failure.

 

 

Monitoring blood pressure at home is an important measure people can take to reduce their risk of a heart attack or stroke. More than 50% of people with high blood pressure who monitor at home show an improvement in medication compliance and are quicker to take action.

 

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
HEALTH

FDA approves Sun’s generic Strattera

BY Allison Cerra

MUMBAI, India A generic drug maker has received regulatory approval for its version of an attention deficit hyperactivity disorder treatment.

Sun Pharmaceutical Industries’ subsidiary has received approval to market its generic version of Strattera (atomoxetine hydrochloride capsules), an ADHD drug for children ages 6 years and older, as well as teens and adults. Strattera is made and marketed by Eli Lilly.

Annual sales of branded and generic atomoxetine hydrochloride capsules are estimated to be more than $530 million.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
HEALTH

Weis Markets announces immunization offerings

BY Michael Johnsen

SUNBURY, Pa. Weis Markets on Tuesday announced it would begin offering flu shots in its in-store pharmacies starting this week. The shots will be administered by its trained and certified pharmacist immunizers through the company’s WeisCare Adult Immunization Services program.

“With our certified pharmacist immunizers, it has never been easier to get a flu shot in a Weis Markets’ store; walk-up immunizations are now available in our pharmacies, and we’re also offering our WeisCare Adult Immunization services to businesses and senior centers in the communities that we serve,” Jeff Maltese, Weis Markets’ VP pharmacy, stated.

The shots are available at Weis Markets’ 120 in-store pharmacies and are available to those 18 years of age and older. For most senior citizens, flu shots are covered by Medicare Part B and Part D. Every flu shot recipient also will receive a money-saving coupon booklet valued at $37, the grocer stated.

Weis Markets pharmacies also offer immunization services for pneumonia, shingles, meningitis, tetanus/diptheria/whooping cough and hepatitis A and B per state regulation.

Later in the fall, Weis Markets also will host 65 flu-shot clinics in its stores.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?